The Essential Protein Engineering and Cell Therapy Summit
May 11th - 13, 2021 | Virtual
Applied BioMath Presence
Presentation: Applied BioMath Assess™: An Early Feasibility Analysis Tool for Biotherapeutics
Presenter: John Burke, PhD, Co-Founder, President and CEO
Presentation Time: Tuesday, May 11th at 10:40 a.m.
Early R&D poses many questions and challenges when determining if a biotherapeutic enters the portfolio, and if so, what are its design characteristics? Some of the questions include an assessment of unmet medical need, competitive landscape, intellectual property, reimbursement, and difficulties of developability. Applied BioMath Assess is a new, interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a therapeutic very early-on in a project.
Presentation: Optimizing multi-specific antibody design with mechanistic avidity models
Presenter: Lucia Wille, PhD
Presentation Time: Thursday, May 13th at 1:40 p.m.
Avid binding of multi-specific antibodies can confer desirable therapeutic properties, such as increased specificity to target cells. However, the design requirements and experimental interpretation are often counterintuitive. Mechanistic models provide clarity to guide development decisions (single-arm affinities, dosing) for desired functionality.